Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.83 +1.9%	$1.81	$1.29 ▼ $13.07	$106.82M	-0.14	717,621 shs	343,689 shs
CYCC Cyclacel Pharmaceuticals	$7.99 -0.1%	$7.80	$3.08 ▼ $597.60	$17.91M	0.08	248,458 shs	42,660 shs
INKT MiNK Therapeutics	$14.90 -0.3%	$14.65	$4.56 ▼ $76.00	$67.62M	0.33	161,830 shs	38,436 shs
INMB INmune Bio	$2.41 +2.6%	$3.35	$1.89 ▼ $11.64	$62.48M	0.97	2.50 million shs	644,216 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	+1.95%	+5.78%	-1.08%	+23.65%	-70.81%
CYCC Cyclacel Pharmaceuticals	-0.12%	+0.50%	-42.93%	-63.26%	-97.23%
INKT MiNK Therapeutics	-0.33%	-0.07%	-25.72%	+109.98%	+77.55%
INMB INmune Bio	+2.55%	-4.74%	-15.73%	-66.99%	-64.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	3.2473 of 5 stars	4.6	3.0	0.0	2.5	0.6
CYCC Cyclacel Pharmaceuticals	0.5288 of 5 stars	0.0	4.0	0.0	2.5	0.0
INKT MiNK Therapeutics	2.8214 of 5 stars	3.3	5.0	1.1	1.7	0.6
INMB INmune Bio	2.0666 of 5 stars	3.3	2.0	1.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.17	Buy	$16.80	818.03% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
INKT MiNK Therapeutics	2.60	Moderate Buy	$37.50	151.68% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	663.49% Upside

Current Analyst Ratings Breakdown

Latest CYCC, INMB, BMEA, and INKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/15/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$35.00 ➝ $35.00
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00
8/6/2025	BMEA Biomea Fusion	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $10.00
8/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/21/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/18/2025	INKT MiNK Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/16/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $9.00
7/15/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$35.00
7/11/2025	INKT MiNK Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.46 per share	N/A
CYCC Cyclacel Pharmaceuticals	$40K	447.44	N/A	N/A	$1.62 per share	4.93
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($5.57) per share	N/A
INMB INmune Bio	$50K	1,281.40	N/A	N/A	$1.09 per share	2.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$138.43M	-$3.03	N/A	N/A	N/A	N/A	-243.95%	-140.74%	11/4/2025 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-723.64%	-145.51%	11/10/2025 (Estimated)
INKT MiNK Therapeutics	-$9.51M	-$2.88	N/A	N/A	N/A	N/A	N/A	-227.24%	N/A
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)

Latest CYCC, INMB, BMEA, and INKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INKT MiNK Therapeutics	-$0.55	-$1.06	-$0.51	-$1.06	N/A	N/A
8/13/2025	Q2 2025	CYCC Cyclacel Pharmaceuticals	-$72.00	-$0.98	+$71.02	-$0.98	$0.03 million	N/A
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.68	3.68
CYCC Cyclacel Pharmaceuticals	N/A	5.77	5.60
INKT MiNK Therapeutics	N/A	0.15	0.30
INMB INmune Bio	N/A	4.20	4.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
CYCC Cyclacel Pharmaceuticals	23.58%
INKT MiNK Therapeutics	2.87%
INMB INmune Bio	12.72%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	18.42%
CYCC Cyclacel Pharmaceuticals	51.20%
INKT MiNK Therapeutics	22.48%
INMB INmune Bio	35.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	59.51 million	48.55 million	Optionable
CYCC Cyclacel Pharmaceuticals	14	2.24 million	773,000	Optionable
INKT MiNK Therapeutics	30	4.52 million	3.51 million	No Data
INMB INmune Bio	10	26.59 million	17.09 million	Optionable

CYCC, INMB, BMEA, and INKT Headlines

Recent News About These Companies

INmune Bio, Inc. (NASDAQ:INMB) Receives $18.40 Consensus PT from Brokerages

4 hours ago | americanbankingnews.com

INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 21 at 3:14 AM | marketbeat.com

INmune Bio Inc. Stock Grades | INMB | Barron's

August 16, 2025 | barrons.com

INmune Bio, Inc. (NASDAQ:INMB) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

BTIG Reaffirms Their Hold Rating on Inmune Bio (INMB)

August 10, 2025 | theglobeandmail.com

Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?

August 10, 2025 | finance.yahoo.com

Inmune Bio (INMB) was downgraded to a Sell Rating at Scotiabank

August 9, 2025 | theglobeandmail.com

Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s

August 9, 2025 | theglobeandmail.com

INmune Bio (INMB) Q2 Loss Widens 110%

August 8, 2025 | aol.comA

INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

INmune Bio stock soars after prostate cancer trial meets endpoints

August 4, 2025 | investing.com

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 4, 2025 | finance.yahoo.com

INmune Bio Shares Surge as Prostate Cancer Trial Achieves Key Goals

August 4, 2025 | msn.com

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 4, 2025 | globenewswire.com

INmune Bio (NASDAQ:INMB) Cut to Sell at Wall Street Zen

August 3, 2025 | marketbeat.com

INmune Bio options imply 14.9% move in share price post-earnings

August 1, 2025 | msn.com

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

July 31, 2025 | globenewswire.com

INmune Bio (INMB) to Release Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

July 29, 2025 | globenewswire.com

2BNS, INMB : INmune Bio Rebounds Sharply During After Hours Trading: What&...

July 28, 2025 | benzinga.com

INmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of "Moderate Buy" by Brokerages

July 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCC, INMB, BMEA, and INKT Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.83 +0.04 (+1.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.81 -0.02 (-1.04%)

As of 08/22/2025 07:56 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$7.99 -0.01 (-0.13%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.03 +0.04 (+0.50%)

As of 08/22/2025 07:48 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

MiNK Therapeutics NASDAQ:INKT

$14.90 -0.05 (-0.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$14.80 -0.10 (-0.70%)

As of 08/22/2025 07:59 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

INmune Bio NASDAQ:INMB

$2.41 +0.06 (+2.55%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.36 -0.05 (-2.03%)

As of 08/22/2025 07:59 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time